Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
NCT ID: NCT05630859
Last Updated: 2025-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
1004 participants
INTERVENTIONAL
2022-11-28
2025-05-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
NCT03629886
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
NCT01190189
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women
NCT01150123
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
NCT00359619
A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age
NCT00657683
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1:1a Low dose Group
Participants randomized to the 1a Low dose Group receive 2 doses of NgG low dose investigational vaccine.
NgG low dose investigational vaccine
Two doses of NgG low dose investigational vaccine, administered intramuscularly.
Phase 1:1b Placebo Group
Participants randomized to the 1b Placebo Group receive 2 doses of placebo.
Placebo
Two doses of placebo, administered intramuscularly.
Phase 1: 2a Medium dose Group
Participants randomized to the 2a Medium dose Group receive 2 doses of NgG medium dose investigational vaccine.
NgG medium dose investigational vaccine
Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
Phase 1: 2b Placebo Group
Participants randomized to the 2b Placebo Group receive 2 doses of placebo.
Placebo
Two doses of placebo, administered intramuscularly.
Phase 1: 3a High dose Group
Participants randomized to the 3a High dose Group receive 2 doses of NgG high dose investigational vaccine.
NgG high dose investigational vaccine
Two doses of NgG high dose investigational vaccine, administered intramuscularly.
Phase 1: 3b Placebo Group
Participants randomized to the 3b Placebo Group receive 2 doses of placebo.
Placebo
Two doses of placebo, administered intramuscularly.
Phase 2: 4a HTD Group
Participants randomized to the 4a highest tolerated dose (HTD) Group receive 2 doses of NgG highest tolerated dose selected from Phase 1.
NgG HTD investigational vaccine
Two doses of NgG HTD investigational vaccine, administered intramuscularly.
Phase 2: 4b dose below HTD Group
Participants randomized to the 4b dose below HTD Group receive 2 doses of NgG dose below the highest tolerated dose selected from Phase 1.
NgG below HTD investigational vaccine
Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
Phase 2: 4c Placebo Group
Participants randomized to the 4c Placebo Group receive 2 doses of placebo.
Placebo
Two doses of placebo, administered intramuscularly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NgG low dose investigational vaccine
Two doses of NgG low dose investigational vaccine, administered intramuscularly.
NgG medium dose investigational vaccine
Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
NgG high dose investigational vaccine
Two doses of NgG high dose investigational vaccine, administered intramuscularly.
Placebo
Two doses of placebo, administered intramuscularly.
NgG HTD investigational vaccine
Two doses of NgG HTD investigational vaccine, administered intramuscularly.
NgG below HTD investigational vaccine
Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Healthy participants as established by medical history, clinical examination, and laboratory assessment.
* A participant between and including 18 and 50 years of age at the time of informed consent.
* Female participants of non-childbearing potential may be enrolled in the study.
* Female participants of childbearing potential may be enrolled in the study if the participant:
* has practiced adequate contraception for 1 month prior to study intervention administration, and
* has a negative pregnancy test on the day of study intervention administration, and
* has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
* Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Healthy participants as established by:
* For the 2 intensive safety monitoring subsets (i.e., first 30 HIV negative subjects per group followed by first 8 HIV positive subjects per group): medical history, clinical examination, and laboratory assessment.
* For all the remaining participants: medical history, clinical examination.
* At risk for gonococcus infections based on sexual behavioral characteristics: this may include men having sex with men, pre-exposure prophylaxis for HIV users, individuals who engage in transactional sex participants with current or past STI diagnosis, participants at time of STI screening or seeking other STI services.
* A participant between and including 18 and 50 years of age at the time of informed consent. Transgender men and women, and other gender non-conforming people who identify themselves as neither men nor women may be enrolled into the study, based on their risk factors. For the purpose of this study, they will be followed up according to their biological sex (sex at birth), sexual orientation, and genital/sexual anatomy
* Participants of non-childbearing potential may be enrolled in the study. This includes transmen that have not undergone gender affirming surgery of their genitals.
* Participants of childbearing potential may be enrolled in the study if the participant:
* has practiced adequate contraception for 1 month prior to study intervention administration, and
* has a negative pregnancy test on the day of study intervention administration, and
* has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
Exclusion Criteria
* Any clinically significant biochemical laboratory abnormality.
* Any other clinical condition as determined by the investigator, that may increase participant's risk due to study participation.
* History of any reaction/hypersensitivity likely to be exacerbated by any component of the study intervention.
* Confirmed or suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination.
* Hypersensitivity to latex.
* Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality, as determined by physical examination/laboratory tests.
* Uncontrolled neurological disorders or seizures.
* History of invasive meningococcal disease. Efficacy PoC part: HIV negative intensive safety monitoring, HIV negative full enrollment and for all remaining participants
* Persons under guardianship or trusteeship.
* Persons deprived of liberty.
* Gonococcal infection identified within 14 days prior to randomization.
* Any other clinical condition as determined by the investigator, that may increase participant's risk due to study participation.
* History of severe allergic reactions and/anaphylaxis, or any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
* Bleeding diathesis / any other condition that would contraindicate intramuscular administration.
* Confirmed or suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination.
* Known seropositivity for HIV infection, regardless of viremia and CD4 cell count
* Hypersensitivity to latex.
* Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality, as determined by physical examination/laboratory tests.
* Recurrent history/uncontrolled neurological disorders or seizures.
* History of invasive meningococcal disease.
Seropositivity for HIV infection if:
* CD4 cell count \< 350 cells/mm3 in the last 6 months
* viral load \> 50cp/ml in the last 6 months
* participant is not on antiretroviral therapy (ART) for \> 3 months or has switched from a different ART in the last 3 months.
For both Intensive safety monitoring subset (first 30 HIV negative subjects per group and first 8 HIV positive subjects per group) these criteria apply:
Any clinically significant hematological/biochemical laboratory abnormality.
2. Prior/Concomitant therapy Applicable for both the dose-escalation safety lead-in part and the PoC part
* Use of any investigational/non-registered product other than the study intervention(s) within 30 days before the first dose/planned use during the study period.
* Previous and planned vaccination with an OMV based Neisseria meningitidis group B vaccine (e.g., Bexsero, MeNZB vaccine or MenBvac at any time prior to first dose and during the entire study period.
* Planned administration/administration of a vaccine not specified in study protocol within 15 days before the first dose and ending 15 days after the last dose of vaccine administration.
* Administration of long-acting immune-modifying drugs during the period starting 6 months prior to the first dose of study intervention/planned administration at any time during the study period.
* Administration of immunoglobulins /any blood products/plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention/planned administration during the study period.
* Chronic administration (more than 14 days in total) of immunosuppressants/other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants/ ≥0.5 mg/kg/day. Inhaled and topical steroids are allowed.
The following criterion applies only for the PoC part:
•Chronic/long-term use of systemic antibiotics with an activity against Neisseria gonorrhoeae.
3. Prior/Concurrent clinical study experience applicable for both dose-escalation safety lead-in part and the PoC part Concurrently participating in another clinical study, at any time during the study period, in which the participant has been/will be exposed to an investigational/a non-investigational intervention.
4. Other exclusions applicable for both dose-escalation safety leading part and the PoC part
* Pregnant/lactating female.
* Female planning to become pregnant/to discontinue contraceptive precautions before 1 month after completion of the study intervention administration series.
* Any study personnel/their immediate dependents, family/household members.
* Lifestyle consideration that may interfere with the conduct of the study/pose additional risks to the rights and wellbeing of participants.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Springfield, Missouri, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Salvador, , Brazil
GSK Investigational Site
Lyon, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Pierre-Bénite, , France
GSK Investigational Site
Bochum, , Germany
GSK Investigational Site
Frankfurt, , Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Johannesburg, , South Africa
GSK Investigational Site
Soweto, , South Africa
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-500883-37-00
Identifier Type: OTHER
Identifier Source: secondary_id
216156
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.